

# Tung-Hung Su

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5624999/publications.pdf>

Version: 2024-02-01

146  
papers

6,085  
citations

101384

36  
h-index

79541

73  
g-index

147  
all docs

147  
docs citations

147  
times ranked

6761  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 424-434.e5.	2.4	9
2	Paradigm shift in the treatment options of hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 2067-2079.	1.9	19
3	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	0.6	63
4	Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities. <i>Gut</i> , 2022, 71, 1238-1240.	6.1	3
5	Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1579-1587.	0.8	4
6	Safety and dose-escalation study of a targeted oncolytic adenovirus, suratadenoturev (OBP-301), in patients with refractory advanced liver cancer: Phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 459-459.	0.8	2
7	Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. <i>American Journal of Gastroenterology</i> , 2022, 117, 748-757.	0.2	15
8	Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level. <i>Scientific Reports</i> , 2022, 12, 5799.	1.6	6
9	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	3.7	237
10	Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. <i>Liver International</i> , 2022, 42, 541-550.	1.9	9
11	Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGF $\beta$ 2 signalling. <i>Gut</i> , 2022, 71, 1876-1891.	6.1	13
12	Clinical manifestations and outcomes of patients with scirrhou hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 472-481.	1.9	4
13	Artificial intelligence in precision medicine in hepatology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 569-580.	1.4	37
14	Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 887-896.	1.0	7
15	Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. <i>Hepatology International</i> , 2021, 15, 582-592.	1.9	5
16	Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2021, 15, 451-458.	1.4	37
17	Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. <i>JHEP Reports</i> , 2021, 3, 100254.	2.6	9
18	APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 833-851.	1.9	43

#	ARTICLE	IF	CITATIONS
19	Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy. Journal of the Formosan Medical Association, 2021, , .	0.8	0
20	Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma. Hepatology International, 2021, 15, 1247-1257.	1.9	6
21	Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. Journal of the Formosan Medical Association, 2021, , .	0.8	10
22	Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. Journal of the Formosan Medical Association, 2021, , .	0.8	8
23	Viral and Host Factors Affecting Disease Progression of Hepatitis B Virus Infection. , 2021, , 205-230.		0
24	Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Alimentary Pharmacology and Therapeutics, 2021, 53, 908-918.	1.9	20
25	Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. Hepatology International, 2021, 15, 1421-1430.	1.9	15
26	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. Alimentary Pharmacology and Therapeutics, 2021, , .	1.9	9
27	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. Journal of Infectious Diseases, 2020, 221, 589-597.	1.9	11
28	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. Journal of Microbiology, Immunology and Infection, 2020, 53, 569-577.	1.5	18
29	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. Journal of Infectious Diseases, 2020, 221, 389-399.	1.9	58
30	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. Liver International, 2020, 40, 758-768.	1.9	24
31	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. International Journal of Cancer, 2020, 147, 901-908.	2.3	5
32	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. Journal of Hepatology, 2020, 72, 839-846.	1.8	49
33	Letter: hepatitis B virus infection and risk of multiple myeloma—a meta-analysis of cohort studies. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 310-311.	1.9	0
34	The concerns of proton pump inhibitors usage in cirrhotic patients with ascites. Advances in Digestive Medicine, 2020, 7, 115-117.	0.1	0
35	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. Journal of Infectious Diseases, 2020, 222, 1345-1352.	1.9	6
36	Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. Advances in Digestive Medicine, 2020, , .	0.1	3

#	ARTICLE	IF	CITATIONS
37	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1871-1875.	0.8	5
38	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1476-1482.	0.8	16
39	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1105-1111.	1.8	43
40	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , 2020, 10, 9180.	1.6	8
41	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	1.0	21
42	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , 2020, 9, 207-220.	4.2	17
43	The clinical manifestations and management of COVID-19-related liver injury. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1016-1018.	0.8	35
44	Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Oncologist</i> , 2020, 25, 793-802.	1.9	13
45	A Mysterious Case of Jaundice After Development of Skin Vesicles. <i>Gastroenterology</i> , 2020, 159, 1669-1671.	0.6	0
46	Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen-“Negative Patients: An Asian Perspective. <i>Clinical Liver Disease</i> , 2020, 16, 244-248.	1.0	1
47	Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 209-221.	3.6	58
48	Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. <i>Movement Disorders</i> , 2019, 34, 1882-1890.	2.2	14
49	High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , 2019, 157, 1518-1529.e3.	0.6	83
50	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 589-598.	1.9	29
51	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1620-1625.	1.4	14
52	Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Children With a Normal Alanine Aminotransferase Level. <i>Hepatology</i> , 2019, 70, 1903-1912.	3.6	11
53	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2179-2186.	1.4	4
54	Risk of liver fibrosis beyond a normal alanine aminotransferase level. <i>Advances in Digestive Medicine</i> , 2019, 6, 1-2.	0.1	0

#	ARTICLE	IF	CITATIONS
55	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1977-1983.	1.4	7
56	Letter to the Editor: Deliberations More Than a Cut-off Hepatitis B Surface Antigen Value for Nucleos(t)ide Analogue Cessation. <i>Hepatology</i> , 2019, 70, 1488-1489.	3.6	1
57	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 410-417.	1.4	11
58	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 331-339.	1.9	11
59	Decreased Colorectal Adenoma Risk After <i>Helicobacter pylori</i> Eradication: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 2105-2113.	2.9	17
60	Age and gender may be the key points in hyperglycemic patients with <i>Helicobacter pylori</i> infection combined colorectal adenoma. <i>Helicobacter</i> , 2018, 23, e12473.	1.6	1
61	HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed?. <i>Hepatology</i> , 2018, 67, 1634-1635.	3.6	11
62	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2018, 217, 1193-1201.	1.9	67
63	Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. <i>Radiology</i> , 2018, 288, 293-299.	3.6	18
64	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 291-297.	1.4	16
65	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 497-504.	0.8	4
66	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 289-292.	2.9	27
67	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2018, 68, 415-424.	3.6	45
68	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 710-717.	1.4	28
69	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0209299.	1.1	13
70	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , 2018, 8, 13699.	1.6	22
71	Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. <i>Journal of Clinical Investigation</i> , 2018, 128, 668-681.	3.9	167
72	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619

#	ARTICLE	IF	CITATIONS
73	Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2017, 37, 310-311.	1.9	1
74	Synergistic Effect of Hyperglycemia and Helicobacter pylori Infection Status on Colorectal Adenoma Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2744-2750.	1.8	20
75	One-Pot Two-Nanoprobe Assay Uncovers Targeted Glycoprotein Biosignature. <i>Analytical Chemistry</i> , 2017, 89, 3973-3980.	3.2	30
76	Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 697-704.	0.8	14
77	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1564-1574.	0.2	44
78	Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 480-481.	1.9	3
79	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 1728.	1.6	13
80	Surveillance of Hepatocellular Carcinoma by Magnetic Resonance Imaging With Liver-Specific Contrast. <i>JAMA Oncology</i> , 2017, 3, 446.	3.4	3
81	Unmet Needs in Clinical and Basic Hepatitis B Virus Research. <i>Journal of Infectious Diseases</i> , 2017, 216, S750-S756.	1.9	21
82	Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx028.	0.4	43
83	High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments. <i>PLoS ONE</i> , 2017, 12, e0170028.	1.1	14
84	Hyperglycemia combined with Helicobacter pylori infection increases risk of synchronous colorectal adenoma and carotid artery plaque. <i>Oncotarget</i> , 2017, 8, 108655-108664.	0.8	17
85	Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. <i>Gut and Liver</i> , 2017, 11, 590-603.	1.4	20
86	Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. <i>Medicine (United States)</i> , 2016, 95, e2995.	0.4	18
87	Hepatitis C viral infection increases the risk of lymphoid neoplasms: A population-based cohort study. <i>Hepatology</i> , 2016, 63, 721-730.	3.6	38
88	Reply. <i>Hepatology</i> , 2016, 64, 1814-1814.	3.6	0
89	Efficacy of entecavir therapy for hepatitis B e antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues. <i>Hepatology Research</i> , 2016, 46, 642-649.	1.8	1
90	Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11937-11942.	3.3	37

#	ARTICLE	IF	CITATIONS
91	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2016, 36, 1755-1764.	1.9	177
92	Multiple Giant Mushroom-like Tumors Inside the Stomach. <i>Gastroenterology</i> , 2016, 151, e9-e10.	0.6	2
93	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 461-468.e2.	2.4	24
94	Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus. <i>Journal of Microbiology, Immunology and Infection</i> , 2016, 49, 941-946.	1.5	5
95	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. <i>Hepatology International</i> , 2016, 10, 294-301.	1.9	3
96	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF- $\kappa$ B signaling and tumor progression in a woodchuck hepatocellular carcinoma model. <i>Oncotarget</i> , 2016, 7, 47173-47185.	0.8	4
97	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015, 5, 11710.	1.6	7
98	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	1.6	8
99	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. <i>Scientific Reports</i> , 2015, 5, 17410.	1.6	13
100	Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 705-713.	1.1	37
101	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015, 64, 303-311.	6.1	39
102	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. <i>Hepatology International</i> , 2015, 9, 35-42.	1.9	12
103	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7243-7248.	3.3	65
104	Advanced Hepatic Fibrosis and Steatosis Are Associated With Persistent Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for Hepatitis C Virus RNA During Pegylated Interferon Plus Ribavirin Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 1429-1436.	1.9	7
105	Improving clinical outcomes of chronic hepatitis B virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 141-154.	1.4	24
106	Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1754-1757.	1.8	62
107	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 949-960.	1.9	49
108	Shear-wave elasticity imaging of a liver fibrosis mouse model using high-frequency ultrasound. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2015, 62, 1295-1307.	1.7	14

#	ARTICLE	IF	CITATIONS
109	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 308-313.	0.8	11
110	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. <i>Gut</i> , 2015, 64, 292-302.	6.1	105
111	Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 1140-1141.	0.8	10
112	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 102-109.	1.4	7
113	Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis. <i>International Journal of Molecular Sciences</i> , 2014, 15, 10578-10604.	1.8	60
114	Shear wave elastography of a liver fibrosis mouse model using a high frequency ultrasound system with mechanical scanning. , 2014, , .		0
115	Younger age and female sex predict a better therapeutic response in HBeAg-positive chronic hepatitis B patients to entecavir therapy. <i>Advances in Digestive Medicine</i> , 2014, 1, 112-117.	0.1	1
116	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , 2014, 34, e71-9.	1.9	14
117	Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: Clinical and mechanistic implications. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1629-1636.	1.4	27
118	Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. <i>Journal of Gastroenterology</i> , 2014, 49, 356-362.	2.3	14
119	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1242-1249.	1.4	16
120	Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 46-50.	1.4	25
121	Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigen-Negative Carriers by Combining Viral Biomarkers. <i>Journal of Infectious Diseases</i> , 2013, 208, 584-593.	1.9	45
122	Milder clinical manifestation of scrub typhus in Kinmen, Taiwan. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 201-207.	0.8	22
123	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013, 57, 934-943.	3.6	47
124	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7844-7849.	3.3	57
125	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , 2013, 57, 441-450.	3.6	227
126	Pegylated Interferon-2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	2.0	91



#	ARTICLE	IF	CITATIONS
127	Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients. PLoS ONE, 2013, 8, e53008.	1.1	47
128	Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection. PLoS ONE, 2013, 8, e55916.	1.1	19
129	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. Antiviral Therapy, 2012, 17, 477-484.	0.6	41
130	Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. Journal of Infectious Diseases, 2012, 206, 1521-1531.	1.9	47
131	Emerging hepatitis B virus infection in vaccinated populations: a rising concern?. Emerging Microbes and Infections, 2012, 1, 1-4.	3.0	13
132	Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. Journal of Infectious Diseases, 2012, 205, 54-63.	1.9	51
133	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. Antiviral Therapy, 2012, 17, 1059-1067.	0.6	23
134	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. Gastroenterology, 2012, 142, 1140-1149.e3.	0.6	469
135	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. Hepatology International, 2012, 6, 598-605.	1.9	2
136	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology, 2012, 55, 68-76.	3.6	130
137	Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. Gastroenterology, 2011, 141, 517-525.e2.	0.6	184
138	The clinical significance of occult hepatitis B transfusion in Taiwan – a lookâ€back study. Transfusion Medicine, 2011, 21, 33-41.	0.5	34
139	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antiviral Therapy, 2010, 15, 1133-1139.	0.6	80
140	HBsAg Profiles in Patients Receiving Peginterferon Alfaâ€a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. Journal of Infectious Diseases, 2010, 202, 86-92.	1.9	46
141	The passage of a colonic cast. Lancet, The, 2010, 375, 2099.	6.3	7
142	Unusual dyspnoea in a patient with liver cirrhosis. BMJ Case Reports, 2009, 2009, bcr0620080250-bcr0620080250.	0.2	0
143	Leakage of air bubbles in subcutaneous emphysema. Resuscitation, 2008, 78, 250-251.	1.3	0
144	Acute Fatty Liver of Pregnancy with Concurrent Acute Hepatitis B Virus Infection. American Journal of Gastroenterology, 2008, 103, 2663-2665.	0.2	0

#	ARTICLE	IF	CITATIONS
145	APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: More questions than answers. <i>Hepatology</i> , 2007, 45, 1586-1587.	3.6	0
146	Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct-acting antiviral-induced sustained virologic response. <i>Advances in Digestive Medicine</i> , 0, , .	0.1	3